JP2016516761A - 炎症性眼疾患の局所治療 - Google Patents

炎症性眼疾患の局所治療 Download PDF

Info

Publication number
JP2016516761A
JP2016516761A JP2016507058A JP2016507058A JP2016516761A JP 2016516761 A JP2016516761 A JP 2016516761A JP 2016507058 A JP2016507058 A JP 2016507058A JP 2016507058 A JP2016507058 A JP 2016507058A JP 2016516761 A JP2016516761 A JP 2016516761A
Authority
JP
Japan
Prior art keywords
compound
alkyl
use according
eye
nalidixic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016507058A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516761A5 (enExample
Inventor
アラン レスリー ロタウル、
アラン レスリー ロタウル、
ジェレミー ギルバート ヴィンター、
ジェレミー ギルバート ヴィンター、
ロバート アーサー スコフィン、
ロバート アーサー スコフィン、
Original Assignee
クレスセット バイオモレキュラー ディスカバリー リミテッド
クレスセット バイオモレキュラー ディスカバリー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201306413A external-priority patent/GB201306413D0/en
Priority claimed from GB201306411A external-priority patent/GB201306411D0/en
Application filed by クレスセット バイオモレキュラー ディスカバリー リミテッド, クレスセット バイオモレキュラー ディスカバリー リミテッド filed Critical クレスセット バイオモレキュラー ディスカバリー リミテッド
Publication of JP2016516761A publication Critical patent/JP2016516761A/ja
Publication of JP2016516761A5 publication Critical patent/JP2016516761A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
JP2016507058A 2013-04-09 2014-04-09 炎症性眼疾患の局所治療 Pending JP2016516761A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1306413.4 2013-04-09
GB201306413A GB201306413D0 (en) 2013-04-09 2013-04-09 The local treatment of ophthalmic diseases
GB1306411.8 2013-04-09
GB201306411A GB201306411D0 (en) 2013-04-09 2013-04-09 Treatment of inflammatory conditions
PCT/GB2014/051108 WO2014167326A1 (en) 2013-04-09 2014-04-09 The local treatment of inflammatory ophthalmic diseases

Publications (2)

Publication Number Publication Date
JP2016516761A true JP2016516761A (ja) 2016-06-09
JP2016516761A5 JP2016516761A5 (enExample) 2017-06-01

Family

ID=50489339

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016507058A Pending JP2016516761A (ja) 2013-04-09 2014-04-09 炎症性眼疾患の局所治療
JP2016507059A Pending JP2016516762A (ja) 2013-04-09 2014-04-09 炎症性障害の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016507059A Pending JP2016516762A (ja) 2013-04-09 2014-04-09 炎症性障害の治療

Country Status (11)

Country Link
US (2) US20160051526A1 (enExample)
EP (2) EP2983713A1 (enExample)
JP (2) JP2016516761A (enExample)
CN (2) CN105431172A (enExample)
AU (2) AU2014252807A1 (enExample)
CA (2) CA2909117A1 (enExample)
GB (2) GB2516137B (enExample)
HK (2) HK1221190A1 (enExample)
RU (2) RU2015145134A (enExample)
WO (2) WO2014167327A1 (enExample)
ZA (2) ZA201507718B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022547541A (ja) * 2019-09-11 2022-11-14 アドヴェラム バイオテクノロジーズ， インコーポレイテッド アフリベルセプトをコードするａａｖ２バリアントを使用して眼内血管新生疾患を処置する方法

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104496986A (zh) * 2014-12-12 2015-04-08 苏州亚科化学试剂股份有限公司 萘啶酸的制备方法
CN108348516B (zh) * 2015-10-29 2021-02-12 特一华制药株式会社 外用剂
AU2017336765B2 (en) 2016-09-28 2023-06-08 Medicon Pharmaceuticals, Inc. Compositions and methods for treating ophthalmic conditions
WO2020021035A1 (en) * 2018-07-26 2020-01-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of antibiotics for the treatment of immunoglobulin a nephropathy
EP3921309A1 (en) * 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Quinolin-4-one and 4(1h)-cinnolinone compounds and methods of using same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005502621A (ja) * 2001-07-06 2005-01-27 スキャンポ アーゲー インターロイキン２阻害剤および抗菌剤を含む局所投与用組成物
JP2008514719A (ja) * 2004-10-01 2008-05-08 ラムズコア， インコーポレイテッド 便利に移植可能な徐放性薬物処方物
JP2012056962A (ja) * 2004-06-24 2012-03-22 Vertex Pharmaceuticals Inc Ａｔｐ結合カセットトランスポーターのモジュレーター
WO2012136969A2 (en) * 2011-04-05 2012-10-11 Anant Sharma Ophthalmic treatments

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19633480A1 (de) * 1996-08-20 1998-02-26 Bayer Ag Oral applizierbare Formulierungen von Chinolon- und Naphthyridoncarbonsäuren
ID23053A (id) * 1997-06-04 2000-01-20 Lilly Co Eli Karboksamida yang digunakan sebagai agonis 5-ht <if>
DE19729879C2 (de) * 1997-07-11 1999-07-08 Mann Gerhard Chem Pharm Fab Lagerstabile ophthalmische Zusammensetzungen, umfassend Diclofenac und Ofloxacin
DE19826050A1 (de) * 1998-06-12 1999-12-16 Bayer Ag Verfahren zur Herstellung von Chinolon- und Naphthyridoncarbonsäuren und deren Ester
CN1090959C (zh) * 1999-06-17 2002-09-18 卢世全 一种治疗咳喘病的中、西复方成药及制备方法
US6552020B1 (en) * 1999-07-30 2003-04-22 Allergan, Inc. Compositions including antibiotics and methods for using same
JP2001342188A (ja) * 2000-03-27 2001-12-11 Takeda Chem Ind Ltd 縮合ピラゾール誘導体、その製造法および用途
JP3648132B2 (ja) * 2000-06-19 2005-05-18 大正薬品工業株式会社 キノロン系抗菌薬液体製剤及びその包装体
AUPS017702A0 (en) * 2002-01-25 2002-02-14 Atopic Pty Ltd Methods and compositions for the treatment of asthma and related disorders
RU2424792C2 (ru) * 2004-05-03 2011-07-27 Хермес Байесайенсиз, Инк. Липосомы, используемые для доставки лекарственных средств
JP2006028031A (ja) * 2004-07-12 2006-02-02 Ltt Bio-Pharma Co Ltd 経粘膜吸収用薬物封入ナノ粒子
JP2009518312A (ja) * 2005-12-02 2009-05-07 ヘルス エンハンスメント プロダクツ インク 疾患を治療するための植物浸出物の組成物および使用
US20080138350A1 (en) * 2006-10-20 2008-06-12 Bennett Michael D Process for use of fluoroquinolones to reduce or modulate inflammation due to eye disease or ophthalmic surgery
CN101129386A (zh) * 2007-07-17 2008-02-27 长治市三宝生化药业有限公司 一种含环丙沙星和地塞米松的局部悬浮滴眼剂
WO2009037855A1 (ja) * 2007-09-21 2009-03-26 Nihon Kodoiryo Kenkyukai Co., Ltd. 口腔用及び皮膚用組成物
GB0719518D0 (en) * 2007-10-05 2007-11-14 Therapeutics Ltd E Therapy
CA2711957C (en) * 2007-10-11 2019-03-19 The Regents Of The University Of California Use of inhibitors of n-acylethanolamine-hydrolyzing acid amidase as anti-inflamatory medicaments
MX342183B (es) * 2008-09-09 2016-09-20 Allergan Inc Suspension oftalmica para uso ocular.
CA2739893C (en) * 2008-10-07 2016-10-04 Mpex Pharmaceuticals, Inc. Inhalation of levofloxacin for reducing lung inflammation
EP2467138A4 (en) * 2009-08-19 2013-11-06 Mpex Pharmaceuticals Inc USE OF AEROSOLIZED ANTIBIOTICS FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE LUNG DISEASE
EP2515907A1 (en) * 2009-12-22 2012-10-31 Deutsches Krebsforschungszentrum Fluoroquinolones for the treatment and/or prophylaxis of inflammatory diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005502621A (ja) * 2001-07-06 2005-01-27 スキャンポ アーゲー インターロイキン２阻害剤および抗菌剤を含む局所投与用組成物
JP2012056962A (ja) * 2004-06-24 2012-03-22 Vertex Pharmaceuticals Inc Ａｔｐ結合カセットトランスポーターのモジュレーター
JP2008514719A (ja) * 2004-10-01 2008-05-08 ラムズコア， インコーポレイテッド 便利に移植可能な徐放性薬物処方物
WO2012136969A2 (en) * 2011-04-05 2012-10-11 Anant Sharma Ophthalmic treatments

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GARIN.M.A. ET AL.: "Experimental corneal infections. Evaluation of nalidixic acid in proteus and pseudomonas keratitis", AMERICAN JOURNAL OF OPHTHALMOLOGY, vol. 66, no. 3, JPN6018015615, September 1968 (1968-09-01), pages 447 - 451, ISSN: 0004104489 *
ノフロ点眼液 0.3% 添付文書, vol. 第2版, JPN6018015617, January 2012 (2012-01-01), ISSN: 0004104491 *
メルク試薬カタログ 2003-2003, JPN6018015613, 1 April 2002 (2002-04-01), pages 1043頁, ISSN: 0004104490 *
尾花 明: "網膜光凝固の変遷と現況", レーザー研究, vol. 第２９巻第７号, JPN6019033519, July 2001 (2001-07-01), pages 438 - 444, ISSN: 0004246177 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022547541A (ja) * 2019-09-11 2022-11-14 アドヴェラム バイオテクノロジーズ， インコーポレイテッド アフリベルセプトをコードするａａｖ２バリアントを使用して眼内血管新生疾患を処置する方法

Also Published As

Publication number Publication date
RU2015145134A3 (enExample) 2018-03-16
GB2516138A (en) 2015-01-14
HK1221166A1 (zh) 2017-05-26
GB201406390D0 (en) 2014-05-21
RU2015145135A (ru) 2017-05-12
WO2014167327A1 (en) 2014-10-16
CA2909111A1 (en) 2014-10-16
US20160051526A1 (en) 2016-02-25
JP2016516762A (ja) 2016-06-09
ZA201507724B (en) 2019-02-27
CN105555364A (zh) 2016-05-04
CA2909117A1 (en) 2014-10-16
GB2516138B (en) 2015-11-25
HK1221190A1 (zh) 2017-05-26
EP2983713A1 (en) 2016-02-17
EP2983788A1 (en) 2016-02-17
RU2015145134A (ru) 2017-05-16
US20160068527A1 (en) 2016-03-10
AU2014252808A1 (en) 2015-11-12
CN105431172A (zh) 2016-03-23
GB2516138C (en) 2015-12-09
ZA201507718B (en) 2019-11-27
GB2516137A (en) 2015-01-14
WO2014167326A1 (en) 2014-10-16
GB2516137B (en) 2016-02-17
GB201406396D0 (en) 2014-05-21
AU2014252807A1 (en) 2015-11-12

Similar Documents

Publication Publication Date Title
JP6629840B2 (ja) 眼の疾患および障害を処置するための化合物
Schopf et al. Topical ocular drug delivery to the back of the eye by mucus-penetrating particles
CN103037857B (zh) 用于治疗/预防眼部炎性疾病的化合物
JP2016516761A (ja) 炎症性眼疾患の局所治療
Bignami et al. Growth inhibition of formed corneal neovascularization following Fosaprepitant treatment
JP2009521493A (ja) 眼への受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の送達のための医薬製剤
JP5557408B1 (ja) 眼底疾患治療剤
AU2014254621B2 (en) Orally administrable pharmaceutical composition for prevention or treatment of dry eye syndrome, comprising rebamipide or prodrug thereof
JP2012524073A (ja) 眼球瘢痕化を抑制するための形質転換成長因子−β受容体阻害剤の使用
US11478465B2 (en) Compounds for treatment of eye diseases associated with excessive vascularisation
JP2017014209A (ja) クエン酸エステルを含有するデポ剤
JP2024506384A (ja) ロフルミラストの眼科的送達方法
EP4405048A1 (en) Methods of treating ocular inflammatory diseases
US20200179482A1 (en) Composition for and method of facilitating corneal tissue repair
US20070093461A1 (en) Effect of Loteprednol etabonate on vascular dysfunction
Wong et al. Liposome drug delivery system: Targeted and sustained delivery of steroid to mitigate the severity of proliferative vitreoretinopathy in a minipig model
JP6835836B2 (ja) 脈絡膜血管新生の処置のための方法及び医薬組成物
HK1214526B (zh) 眼底疾病治疗剂
EA045318B1 (ru) Соединения для лечения глазных болезней, связанных с избыточной васкуляризацией
Bhartiya et al. A Comparative Study of the Anti-inflammatory effect of Topical 1% Prednisolone and Topical 0.1% Dexamethasone Eye Drops after Cataract Surgery in Western Uttar Pradesh
Banz et al. Calming the Ocular Storm
HK1246167B (zh) 含有柠檬酸酯的贮库制剂
JPH08104630A (ja) 眼炎症及び／又は創傷の予防及び治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180807

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190405

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190903

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200407